Interferon Beta-1a
Brand name: Avonex
Rank #163 of 500 drugs by total cost
$98.3M
Total Cost
11,314
Total Claims
$98.3M
Total Cost
652
Prescribers
$8,685
Cost per Claim
17
Beneficiaries
11,830
30-Day Fills
$151K
Avg Cost/Provider
17
Avg Claims/Provider
About Interferon Beta-1a
Interferon Beta-1a (sold as Avonex) was prescribed 11,314 times by 652 Medicare Part D providers in 2023, costing the program $98.3M. At $8,685 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 160 | Omalizumab (Xolair) | $98.9M | 30,451 |
| 161 | Brimonidine Tartrate (Alphagan P) | $98.8M | 988,570 |
| 162 | Dexlansoprazole (Dexlansoprazole Dr) | $98.7M | 275,116 |
| 163 | Interferon Beta-1a (Avonex) | $98.3M | 11,314 |
| 164 | Guselkumab (Tremfya) | $97.1M | 7,102 |
| 165 | Levetiracetam (Levetiracetam) | $96.1M | 1,723,736 |
| 166 | Oxycodone Myristate (Xtampza Er) | $96.1M | 141,266 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology